

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE

The board (the “**Board**”) of directors (the “**Directors**”, and each, a “**Director**”) of the Touyun Biotech Group Limited (the “**Company**”) announces that (i) Mr. Wang Liang, an existing executive Director, has ceased to be a member and the chairman of the nomination committee of the Board (the “**Nomination Committee**”), (ii) Mr. Du Dong, an existing executive Director, has been ceased to be a member of the Nomination Committee and (iii) Mr. Cheung Wing Ping, an existing independent non-executive Director and a member of the Nomination Committee, has been appointed as the chairman of the Nomination Committee, with effect from 4 July 2025.

Following the above changes, the Nomination Committee comprises three members, namely Mr. Cheung Wing Ping (Chairman), Mr. Ha Kee Choy Eugene and Ms. Tian Yuze.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 4 July 2025

As at the date of this announcement, the Board comprises the following directors:

Executive Directors

Mr. Wang Liang (*Chairman*)
Mr. Du Dong

Non-executive Directors

Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele

Independent Non-executive Directors

Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen